{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:17:08Z","timestamp":1790781428168,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clml.2024.10.002","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:25:55Z","timestamp":1728505555000},"page":"26-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brazilian Real-Life Experience of Multiple Myeloma (MMyBRAve): Improvement in Outcomes, But Remaining Diagnostic and Therapeutic Gaps"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-1957","authenticated-orcid":false,"given":"Vania","family":"Hungria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosane Isabel","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2598-2760","authenticated-orcid":false,"given":"Gracia Aparecida","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-986X","authenticated-orcid":false,"given":"Juliana de Andrade","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Ramos","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9471-1369","authenticated-orcid":false,"given":"Vera Lucia de Piratininga","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Le\u00e3o Cordeiro","family":"de Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla Richter","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9403-4847","authenticated-orcid":false,"given":"Larissa Barchi","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Tosta","family":"Senra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Martins","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9derson Roberto","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.10.002_bib0001","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.10.002_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2024.10.002_bib0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.10.002_bib0004","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.10.002_bib0005","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.10.002_bib0006","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.10.002_bib0007","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.10.002_bib0008","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.10.002_bib0009","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.10.002_bib0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.10.002_bib0011","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/14656566.2022.2101362","article-title":"On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future","volume":"23","author":"Sunder-Plassmann","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2024.10.002_bib0012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1590\/1516-3180.2015.0223030416","article-title":"Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study","volume":"134","author":"Kerbauy","year":"2016","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.clml.2024.10.002_bib0013","unstructured":"Health and health care in Brazil. Brazil provides free, universal access to medical care to anyone legally living in the country. Available at: https:\/\/www.aetnainternational.com\/en\/individuals\/destination-guides\/expat-guide-to-brazil\/health-and-health-care.html (Accessed: February 2024)."},{"key":"10.1016\/j.clml.2024.10.002_bib0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/pds.1082","article-title":"International Society of P. Guidelines for good pharmacoepidemiology practices (GPP)","volume":"14","author":"Epstein","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clml.2024.10.002_bib0015","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.10.002_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","article-title":"Observational study of multiple myeloma in Latin America","volume":"96","author":"Hungria","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2024.10.002_bib0017","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","article-title":"Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"Pessoa de Magalhaes Filho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.10.002_bib0018","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3324\/haematol.11637","article-title":"Confirmation of the utility of the international staging system and identification of a unique pattern of disease in Brazilian patients with multiple myeloma","volume":"93","author":"Hungria","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.10.002_bib0019","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.16124","article-title":"Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) observational study, 2008-2016","volume":"188","author":"de Moraes Hungria","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T06:39:20Z","timestamp":1736059160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2152265024023619"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brazilian Real-Life Experience of Multiple Myeloma (MMyBRAve): Improvement in Outcomes, But Remaining Diagnostic and Therapeutic Gaps","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}